| DATE: December 5, 2024 | | |
| --- | --- | --- |
| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Strawpoll sent with these minutes |
| Guidelines in-progress | Guidelines   * *CYP3A5*/Tacrolimus – In evidence review * *CYP2D6*/Antipsychotics – In evidence review; the authors are discussing adding more genes * *NAT2*/Hydralazine – Drafting guideline * *UGT1A1*/irinotecan- On hold because of re-prioritization for DPYD and *TPMT/NUDT15* updates (new evidence that might affect recommendation). Planning to begin in February. * DPYD/fluoropyrimidines- Evidence review underway * *TPMT-NUDT15*/thiopurines update - Evidence review almost complete * *CYP2D6*/ondansetron - Authorship plan underway * *NAT2* isoniazid – Call for authors in February | Kelly will continue to update  To see the guidelines currently being developed go to:  https://cpicpgx.org/prioritization-of-cpic-guidelines/ |
| New SNOMED/IMO terms | Based on the CPIC statin guideline, *ABCG2* SNOMED terms/codes were approved in SNOMED. *MT-RNR1* and *G6PD* variable SNOMED codes have been recently requested. *NAT2* SNOMED codes will be requested once guideline is published. If there are other PGx terminologies for which SNOMED codes should be created, please notify Kelly. | Email [Kelly](mailto:kelly.caudle@stjude.org) if there are additional SNOMED codes you believe should be created. |
| *NAT2*/hydralazine nomenclature | Kelly Caudle, PharmD, PhD, CPIC and St. Jude Children’s Research Hospital, presented on NAT2 nomenclature. |  |
| Therapeutic recommendations for hydralazine  therapy related to *NAT2* phenotype | Michael Eadon, MD, Indiana University School of Medicine, presented “Therapeutic recommendations for hydralazine therapy related to NAT2 phenotype”. | Guideline will be circulated to all CPIC members once complete (~February) for CPIC review. |
| NAT2 Survey regarding appropriate phenotype and allele function terminology | CPIC members are encouraged to take [this survey](https://qualtricsxmhypknk4b9.qualtrics.com/jfe/form/SV_3Q8YqS4FYzPPO86). |  |

REMINDER: REA PGx survey

Dear CPIC Member,

We are excited to invite you to participate in a research study titled "Perceptions and Practices of Pharmacogenomic Stakeholders Regarding the Collection and Application of Race, Ethnicity, and Ancestry Data." This study aims to explore the current trends and practices within the field of pharmacogenomics regarding the collection and utilization of race, ethnicity, and ancestry data.

Your expertise and experience in pharmacogenomics make you an invaluable contributor to this research. By participating, you will help us understand the diverse perspectives and methodologies in use today, which can ultimately inform best practices and enhance the field. The survey will take approximately 5-15 minutes to complete. At the end of the survey, you will be asked if you would like to be entered into a drawing to win one of five $50 USD electronic Amazon gift cards. Your responses will be kept confidential and used solely for research purposes. To participate, please click on the link below:

[https://redcap.link/1zqecv7x](https://secure-web.cisco.com/1rWq95BHirwUtBA8FRXxUYbYPwcr0msDpnOdG2lG7PBUGdW04CsQVhVKWpgbY6DLGwNMi0Lt4FehEbNfPrtLHr1w2Dkf-n_jQw8N39AJDcRNhJ9OGVDvEa5IPGsJYbZba4Vz7j-CYOwUU7pJ8GYNXSEzF4IjWspSFftEEktrHaDIGP901u8KkfbUDIysZA2K9qriM1GlEjK0bS1IKnMdlXo4eQgePst8MYpnNTKYhc7sarL7XGYiJ5PqtE1rg-WG75Egmd_iBmvYFWQCabLvIsATnAm1hZK3ys2afEQREMC8hjj5bcRbWXVpTiyiQVrTl_r3KPawp6wacdg2Kean5ZA/https%3A%2F%2Fredcap.link%2F1zqecv7x)

We encourage you to share this survey with your colleagues who are also involved in pharmacogenomics. Broadening our reach will enrich the data and ensure a comprehensive understanding of the field.

Thank you in advance for your time and contribution to this important study. Please do not hesitate to contact us if you have any questions or require further information.

Warm regards,

Brittany Stokes BS, MS-GC '25 MGH-IHP

[bstokes@mghihp.edu](mailto:bstokes@mghihp.edu)

Elizabeth Fieg MS, CGC

[efieg@bwh.harvard.edu](mailto:efieg@bwh.harvard.edu)